Legend Biotech ( LEGN +18.42%) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

If biotech funding continues to increase this year, Danaher could benefit.

We'll know more about the company's medium-term prospects by the end of the year.

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

Introducing CPC Biotech - one brand uniting critical fluid management components New brand unites CPC’s Biopharma connector ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

John Crowley, Biotechnology Innovation Organization (BIO) president and CEO, joins 'Squawk Box' to discuss 50 years of ...

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...